2 shares I’m avoiding after FY results

Two companies with mixed figures one Fool is personally avoiding.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In the deluge of company results published today, two reports stand out to me as being some of the worst.

Bodycote (LSE: BOY) and Exova Group (LSE: EXO) have both published numbers today that look good on the outside, but seem less than attractive to me personally when you dig below the surface.

Positive reaction 

The market has reacted positively to Bodycote’s numbers, sending the shares up by 8% in early trading. The company reported statutory profit before tax of £92m for the year ended 31 December 2016 compared to £75m for the previous year. However, last year the company booked a large one-off restructuring charge of £20m, which depressed the statutory figures. Excluding this charge, pre-tax profit for 2015 would have been £99.2m. Using the same adjusted figures, pre-tax profit for 2016 came in at £97m. So, on an adjusted basis Bodycote’s profit fell 2.2% for the year.

Should you invest £1,000 in Bodycote Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Bodycote Plc made the list?

See the 6 stocks

What’s more, while headline revenue expanded 5.9% year-on-year, Bodycote’s return on sales and return on capital employed fell to 16.6% from 18% and to 17.7% from 19% respectively. It seems the restructuring of the business has done little to improve margins. The firm’s net cash balance declined from £12.3m to £1.1m, and headline earnings per share fell 6.3%.

Considering these figures, it seems strange to me that the market has reacted so positively to Bodycote’s full-year numbers. The shares are currently trading at a P/E of 19.1 based on today’s numbers, which seems too generous for the company’s sluggish growth. This year, City analysts have pencilled in earnings per share growth of 7% better than 2016’s earnings contraction but arguably still too little too late for the business.

A worrying trend

Like Bodycote, Exova’s positive headline figures are also hiding a worrying underlying trend. For the year ending 31 December 2016, Exova reported revenue growth of 10.8%, which includes a substantial benefit from sterling’s depreciation. 

At constant currency, revenue grew 2.4%, but once again this figure has been influenced by additional factors namely bolt-on acquisitions. Stripping out the impact of acquisitions and disposals, organic revenue declined by 0.2%. And just like Bodycote, Exova has been able to inflate its figures thanks to a one-off restructuring charge booked last year. 

The group’s statutory results show pre-tax profit growth of 57.8% from £36.6m to £23.2m year-on-year. If you take away these costs pre-tax profit grew by a more subdued 8% year-on-year that’s including the impact of currency. Considering the weak sterling boosted top-line revenue by 10.8%, it’s reasonable to assume that without this leg up, Exova’s pre-tax profit growth would have been negative.

Shares in Exova currently trade at a forward P/E of 16.6 based on City estimates for 2017 growth. For 2017 analysts are forecasting a decline in earnings per share of 3%. With this being the case, and considering the company’s poor results for 2016, I’m avoiding Exova for the time being.

Pound coins for sale — 31 pence?

This seems ridiculous, but we almost never see shares looking this cheap. Yet this Share Advisor pick has a price/book ratio of 0.31. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 31p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 10%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has recommended Bodycote. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Up 30% in weeks, does the BAE Systems share price still offer value?

The BAE Systems share price has been on a tear over the past couple of months. This writer sees limited…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Hunting for shares to buy as the market trembles? Remember this!

After a choppy week in global stock markets, our writer goes back to basics in his hunt for bargain shares…

Read more »

Investing Articles

3 simple principles to help build wealth in an ISA

As a new tax year opens up new ISA allowances for many investors, our writer shares a trio of things…

Read more »

Investing Articles

US trade tariffs: what they could mean for UK shares like Ashtead, Compass Group, and Experian

US trade tariffs continue to rock global markets, and the UK is no exception. Our writer considers how a new…

Read more »

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Dividend Shares

The Trump slump has smashed these FTSE 100 shares!

After a rough week for US and UK shares, investors have been shaken. But now these FTSE 100 stocks have…

Read more »

Investing Articles

£10,000 invested in Rolls-Royce shares 5 years ago is now worth…

Rolls-Royce shares have been on fire since April 2020. Part of this is the result of pandemic restrictions lifting, but…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

£10,000 invested in Tesla stock at its peak in 2024 is now worth…

Over the last few months, Tesla stock has lost nearly half its value. Here, Edward Sheldon explores a few takeaways…

Read more »

Investing Articles

Is the S&P 500 heading for an epic stock market crash?

Our writer shares his thoughts on a very crazy time for the S&P 500 and the wider stock market. How…

Read more »